D-Cubed Series: Article 2 – The Competitive Divide of Real-World Data in Healthcare

The shift toward D-Cubed Pharma is recent, emerging only in the past 1–3 years. The competitive map looks very different from traditional measures of success. Infrastructure alone no longer defines leadership. What matters now is recency of action, boldness of experimentation, and willingness to ditch legacy playbooks. What is needed is real-world data in healthcare to drive activation at the right time.

We ranked pharma not by pipeline size or sales force reach, but by visible evidence of recent D-Cubed adoption. However, every pharma company today has the capability of accelerating investment in D-Cubed dynamics.

D-Cubed Adoption Spectrum

Tier 1 — D-Cubed Architects: AstraZeneca, Roche, AbbVie

Tier 2 — D-Cubed Capable: Pfizer, Merck, Lilly, J&J

Tier 3 — Selective Adopters: scattered pilots, lacking orchestration: BMS, Sanofi, GSK

Cynic’s Corner (Part 2)

Is D-Cubed just a macro hypothesis? No. The building blocks are visible today:

• Reflex testing pathways funded at scale
• Funnels that are built by real-world data in healthcare, tracking tested to treated
• Digital triggers embedded in networks
• Navigation apps and lab-finders launched alongside drugs

D-Cubed is not theory. It is an emerging operating model, observable today.

D-Cubed Proof in Practice: Physician Engage

The evolving D-Cubed model is already reshaping how leading organizations execute in complex therapy areas. Diagnosis of Myeloid Malignancies is fragmented and time-sensitive. Data is often dispersed. One global pharma company advanced its engagement model by integrating diagnostics-triggered insights with real-world data in healthcare and precision digital activation.

Rather than adding more of the same tactics, the team rebalanced its launch mix to activate physicians at the true point of decision. Using multimodal real-world data in healthcare, such as daily lab alerts, Physician Engage identified treating HCPs at diagnosis. It delivered tailored, relevant content through trusted digital channels within 24 hours.

In six months, the initiative identified 2,398 patients. It was able to engage 384 physicians and achieved a 7x return on investment. And all this while enabling faster, more equitable treatment access.*

This is the competitive divide we are describing here: organizations that operationalize D-Cubed behaviors. Diagnostics triggers, data-led targeting, and digital activation allow the ability to compound capability.

They build a scalable, repeatable model. One that accelerates therapy adoption and raises the bar for what effective launch execution looks like.

*Source: Diaceutics’ client projects

This article builds on the concepts introduced in the first article of this series: D-Cubed Pharma: The $20B ROI Advantage.